Pegylated interferon therapy of chronic hepatitis D: In need of revision

Hepatology

Volumn 61, Issue 4, 2015, Pages 1109-1111

  Rizzetto, Mario ^a   Smedile, Antonina ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LIVER ENZYME; LONAFARNIB; PEGINTERFERON; TENOFOVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL PRACTICE; DELTA AGENT HEPATITIS; DRUG EFFICACY; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIMIT OF DETECTION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA INTERFERENCE; TREATMENT RESPONSE; VIROLOGY; VIRUS DETECTION; HEPATITIS D, CHRONIC;

ANTIVIRAL AGENTS; HEPATITIS D, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84925373642     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27585     Document Type: Article

References (20)

1. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005;12:2-9.
2. Ciancio A, Rizzetto M. Peg-IFN for the treatment of hepatitis D. Nat Rev Gastroenterol Hepatol 2011;8:304-306.
3. Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a real world experience. Antivir Ther 2014;19:463-468.
4. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006;44:728-735.
5. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-331.
6. Heidrich B, Yurdaydin C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014;60:87-97.
7. Triantos C, Kalafateli M, Nikolopoulou V, Burroughs A. Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther 2012;35:663-673.
8. Ponzetto A, Hoyer BH, Popper H, Engle R, Purcell RH, Gerin JL. Titration ofthe infectivity of hepatitis D virus in chimpanzees. J Infect Dis 1987;155:72-78.
9. Olivero A, Smedile A. Hepatitis delta virus diagnosis. Semin Liver Dis 2012;32:220-227.
10. Taylor JM. Structure and replication of hepatitis delta virus RNA. Curr Top Microbiol Immunol 2006;307:1-23.
11. Sureau C. The role of the HBV envelope proteins in the HDV replication cycle. Curr Top Microbiol Immunol 2006;307:113-131.
12. Lamers MH, Kirgiz ÖÖ, Heidrich B, Wedemeyer H, Drenth JP. Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther 2012;17:1029-1037.
13. Wedemeyer H, Yurdaydin C, Ernst S, Caruntu FA, Curescu MG, Yalcin K, et al. Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: The HIDIT-2 study. EASL 2014, April 9-13, London, UK. J Hepatol 2014;60(Suppl):S2-S3.
14. Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol 2014;11:68-71.
15. Ouzan D, Pénaranda G, Joly H, Halfon P. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta. J Hepatol 2013;58:1258-1259.
16. Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 2014;40:93-104.
17. Chudy M, Hanschmann KM, Bozsayi M, Kress J, Nubling CM. Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technology (NAT)-based assays. WHO Report 2013. WHO/BS/2013.2227. Available at: http://www.who.int/biologicals/expert_committee/BS_2227_HDV_RNA.pdf. Accessed November 6, 2014.
18. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014;146:1070-1083.
19. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014;147:48-64.
20. Glenn JS. Prenylation of HDAg and antiviral drug development. Curr Top Microbiol Immunol 2006;307:133-149.